AVTX earnings analysis
What we found in AVTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Avalo Therapeutics reported a net loss of $19.6 million for Q1 2026 with no revenue being generated, consistent with its ongoing clinical development phase for abdakibart. The company secured $431.3 million in funding from a recent equity offering and reported strong Phase 2 trial results, setting a positive outlook for advancing abdakibart into Phase 3 trials.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Positive Phase 2 Trial Results
- The LOTUS trial for abdakibart achieved primary endpoint success rates of 42.2% and 42.9%, establishing it as a significant advancement in the clinical program.
- Strong Cash Position
- Avalo secured approximately $431.3 million in gross proceeds from a recent equity financing, enhancing its liquidity.
- Operational Cash Flow Improvement
- Net cash used in operating activities increased by $8.2 million, from $9.5 million in Q1 2025 to $17.7 million in Q1 2026.
- Research and Development Increase
- R&D expenses grew from $9.1 million in Q1 2025 to $14.0 million in Q1 2026, reflecting advancements towards a Phase 3 program.
- General and Administrative Expense Growth
- G&A expenses rose from $5.5 million in Q1 2025 to $6.9 million in Q1 2026, driven by increased salaries and stock-based compensation.
- High Cash and Cash Equivalents
- As of March 31, 2026, Avalo held $82.0 million in cash and cash equivalents, sufficient to fund operations into 2029.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Losses
- Net loss for Q1 2026 was $19.6 million, which may impact future funding and operational strategy.
- Rising Operating Expenses
- Operating expenses rose significantly, with total expenses growing due to headcount increases and clinical trial costs.
- Regulatory Approval Risks
- Advancing abdakibart into Phase 3 trials involves significant risks and uncertainties regarding FDA approval.
What they said about what is next.
Outlook includes potential advancements in product development, but no explicit numeric guidance is provided.
The filing reads better than the one before it.
What came before.
- 10-K · March 23, 2026
- Avalo is a clinical-stage biotech focused on IL‑1β biology with its lead candidate abdakibart (AVTX‑009) — enrollment for the Phase 2 LOTUS HS trial (~250 patients) was completed in October 2025 and topline data are…
- 10-Q · November 6, 2025
- Avalo reported zero revenue and a third-quarter net loss of $30,625,000 (net loss per share -$2.19) with operating loss of $19,198,000. Management states it has $111.6 million of cash and short-term investments and…
- 10-Q · May 12, 2025
- Avalo reported Q1 2025 GAAP loss per share of $(1.25) driven by a net loss of $(13.15) million, an improvement from a $(121.29) million loss in Q1 2024. The company recognized no revenue in the quarter, ended March 31,…
- 10-K · March 20, 2025
- Avalo Therapeutics is a clinical‑stage biotech centered on AVTX-009 (anti‑IL‑1β), having dosed the first patient in its Phase 2 LOTUS trial in October 2024 (≈180 patients, randomized 1:1:1, 16‑week treatment with…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AVTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever